Drug Trial Radar · NCT05629546
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Nov 6, 2024
Primary completion
Feb 28, 2029
Study completion Nov 30, 2030
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Melanoma Research Alliance; Rising Tide Foundation
- First posted
- Nov 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML NK cells from either an autologous source or allogeneic source are safe and tolerable in subjects with advanced and/or metastatic melanoma.
Conditions
- Advanced Melanoma
- Metastatic Melanoma
Interventions
Cytokine-induced memory-like natural killer cellsBiological
Cell product processing is performed at the Siteman Cancer Center Biological Therapy Core Facility (BTCF).
RelatilmabBiological
Standard of care
NivolumabBiological
Standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- For treatment with cells from an autologous source: Incidence and severity of adverse eventsTime frame: From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
- For treatment with cells from an allogeneic source: Incidence and severity of adverse eventsTime frame: From start of lymphodepleting chemotherapy (Day -6) through end of safety follow-up (estimated to be 15 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.